<DOC>
	<DOCNO>NCT02580747</DOCNO>
	<brief_summary>RATIONALE : Placing tumor antigen chimeric receptor create laboratory patient autologous donor-derived T cell may make body build immune response kill cancer cell . PURPOSE : This clinical trial study genetically engineer lymphocyte therapy treat patient Relapsed and/or Chemotherapy Refractory Advanced Malignancies .</brief_summary>
	<brief_title>Treatment Relapsed and/or Chemotherapy Refractory Advanced Malignancies CART-meso</brief_title>
	<detailed_description>I . Determine safety feasibility chimeric antigen receptor T cell transduce anti-meso vector ( refer CART-meso cell ) . II . Determine duration vivo survival CART-meso cell . RT-PCR ( reverse transcription polymerase chain reaction ) analysis whole blood use detect quantify survival CART-meso TCR ( T-cell receptor ) zeta : CD137 time . SECONDARY OBJECTIVES : I . For patient detectable disease , measure anti-tumor response due CART-meso cell infusion . II . Estimate relative traffic CART-meso cell tumor bone marrow lymph node . III . For patient store accessible tumor cell determine tumor cell kill CART-meso cell vitro . IV . Determine cellular humoral host immunity develop murine anti-meso , assess correlation loss detectable CART-meso ( loss engraftment ) . V. Determine relative subset CART-meso T cell ( Tcm , Tem , Treg ) .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>1 . Chemotherapy refractory relapse mesothelin positive malignant mesothelioma , ovarian tumor , pancreatic cancer , triple negative breast cancer , endometrial cancer mesothelin positive tumor 2 . Patients must 18 year age old . 3 . Patients must ECOG ( Eastern Cooperative Oncology Group ) performance status 02 . 4 . Patients must evidence adequate bone marrow reserve , hepatic renal function evidence follow laboratory parameter : Absolute neutrophil count great 1500/mm3 . Platelet count great 100,000/mm3 . Hemoglobin great 10g/dl ( patient may receive transfusion meet parameter ) . Total bilirubin &lt; 1.5 time upper limit normal . Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m . 5 . Seronegative HIV antibody . 6 . Seronegative active hepatitis B , seronegative hepatitis C antibody . 7 . Patients must willing practice birth control four month follow treatment . NOTE : woman childbearing age must evidence negative pregnancy test . 8 . Patients must willing sign inform consent . 1 . Patients life expectancy le 12 month exclude . 2 . Patients uncontrolled hypertension ( &gt; 160/95 ) , unstable coronary disease evidence uncontrolled arrhythmia , unstable angina , decompensated congestive heart failure ( &gt; New York Heart Association Class II ) , myocardial infarction within 6 month study exclude . 3 . Patients follow pulmonary function abnormality exclude : FEV ( forced expiratory volume ) , &lt; 30 % predict ; DLCO ( diffuse capacity lung carbon monoxide ) &lt; 30 % predict ( postbronchodilator ) ; Oxygen Saturation less 90 % room air . 4 . Patients severe liver kidney dysfunction consciousness disorder exclude . 5 . Pregnant and/or lactate woman exclude . 6 . Patients active infection , include HIV , exclude , due unknown effect vaccine lymphoid precursor . 7 . Patients type primary immunodeficiency exclude study . 8 . Patients require corticosteroid ( inhale ) exclude . 9 . Patients history T cell tumor exclude . 10 . Patients participate participated clinical trial late 30 day exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>